Where the 19,000-injection figure comes from

The figure of 19,000-plus injections is not a marketing estimate. It originates in Meidrix Biomedicals GmbH's Clinical Evaluation Report (CER), Version 09, dated 30 April 2025 — a mandatory regulatory document that any manufacturer must file and maintain to hold CE Class III certification under the EU Medical Device Regulation. Class III is the highest-risk tier in the European framework, reserved for devices that interact directly with living tissue; the level of scrutiny applied is correspondingly rigorous.

The cumulative treatment count within that report sits at 19,000–19,400 cases by mid-2026, and the number continues to grow with each new injection administered. It is drawn from three distinct evidence streams: post-market clinical follow-up (PMCF) studies, prospective cohort data, and real-world registry records collected across multiple countries. The knee accounts for the largest share of cases, but the dataset also spans hip, ankle, shoulder, wrist, and smaller hand and foot joints.

ChondroFiller has been in routine clinical use since 2013, which means the evidence base reflects more than a decade of continuous, audited post-market surveillance — not a single trial run in controlled conditions. The device holds CE Class III certification in Europe and is not approved by the US Food and Drug Administration; it is currently unavailable in the United States.

The safety numbers and what they compare against

Across the pooled dataset of 19,000-plus cases, no serious adverse device effects (SADEs) have been reported. The device-related complication rate is cited in CER v09 as approximately 0% — a figure drawn from PMCF studies, prospective cohort data, and real-world registry records, making the evidence architecture internally consistent rather than reliant on a single source.

The reoperation rate across published ChondroFiller cohorts sits at 3–8%. To contextualise that figure, CER v09 draws on the same evidence base to report outcomes for the two main surgical repair alternatives: microfracture carries a reoperation rate of up to 41% and a complication rate of 0–7%, while autologous chondrocyte implantation (ACI or MACI) carries a reoperation rate of up to 37% and a complication rate of up to 17%. These are operative procedures requiring theatre admission and anaesthesia; the ChondroFiller pathway, by contrast, is delivered as an ultrasound-guided outpatient injection. That difference in setting and invasiveness is relevant when interpreting the comparison, and the figures are not presented here to imply clinical equivalence in every respect — patient selection, defect size, and surgical skill all affect surgical outcomes independently.

The one device-specific technical failure mode is non-gelation — the liquid collagen scaffold failing to set after injection. This occurs in fewer than 0.01% of administrations, meaning the product behaves as intended in more than 99.99% of cases. Non-gelation is a product-performance event rather than a patient-harm event; it does not cause tissue damage.

Side effects patients typically experience

Most patients notice three things in the 48–72 hours after treatment: some localised swelling around the joint, a brief intensification of pain, and a degree of stiffness that gradually eases. These are entirely consistent with any intra-articular injection — the joint responding to the needle and the introduced volume — rather than a signal specific to the collagen scaffold itself.

The one risk that is particular to ChondroFiller is fibrous tissue formation inside the joint. This can occur if the liquid collagen is placed beyond the boundary of the cartilage defect rather than flush within it, prompting the surrounding tissue to react to material that has strayed outside its intended site. Critically, this is a technique-dependent issue, not an inherent property of the collagen material. Correct placement within the defect boundary is straightforward to achieve under real-time ultrasound guidance, which is standard in the current service pathway; when the scaffold is positioned accurately, the risk does not arise.

No systemic reactions — such as allergic cascades or widespread inflammatory responses — have been recorded in the pooled clinical dataset, consistent with the known biocompatibility profile of purified Type I collagen scaffolds.

How outcomes hold up at one year and beyond

Between 70 and 85% of patients treated across published ChondroFiller cohorts report meaningful reduction in pain and improved joint mobility — a useful starting point before examining what the functional measurements show in detail.

In knee studies, IKDC scores — a validated patient-reported measure of knee function — improve by approximately 30 points over 12 months. The clinically important threshold for this scale is 16.7 points: any improvement beyond that figure crosses what researchers call the minimal clinically important difference (MCID), the point at which a score change translates into something the patient actually notices in daily life. The Jerosch et al. prospective PMCF study tracked this further, recording a mean improvement of 32.4 points that was sustained — and slightly increased — at three-year follow-up, with patients reaching a mean IKDC score of 80.1.

Imaging data tell a complementary story. MOCART scores, which measure cartilage repair quality on MRI, capture how well the defect is filling in. In one key study, scores rose from 65.3 at four weeks post-injection to 81.6 at one year — a trajectory that reflects the scaffold gradually recruiting the body's own cells and supporting new tissue formation rather than producing an instant result. Across European cohorts, MOCART ranges from 81.6 to 84.3, indicating that more than 80% of the defect has been structurally filled and integrated with the surrounding cartilage.

Post-treatment MRI scans also show reductions in swelling within the bone beneath the joint surface, less fluid pooling around the joint, and increased visible space between the articulating bones — all objective signs that the scaffold is being tolerated and integrated without provoking a harmful tissue response.

What the evidence cannot yet tell us

Three honest limits sit alongside the safety and outcomes record described above.

First, the evidence is manufacturer-compiled. All data feeding CER v09 — the PMCF studies, prospective cohorts, and registry observations across more than 19,000 treatments — was gathered and assembled by Meidrix Biomedicals GmbH as part of its mandatory EU MDR regulatory obligation. No independent registry, external systematic review, or blinded randomised controlled trial currently exists. The absence of an RCT also means that the reoperation comparison with microfracture and ACI/MACI draws on cross-study figures rather than head-to-head randomised data: the populations, follow-up durations, and defect criteria across those studies may differ in ways that affect the absolute numbers.

Second, ChondroFiller is designed for a specific structural injury — a focal cartilage defect — and the published experience does not extend to generalised joint wear or advanced osteoarthritis. The safety and efficacy record is an accurate reflection of outcomes in patients selected for that indication; it should not be read as evidence for a wider one.

The evidence base is not fixed. CER v09, dated April 2025, is the ninth iteration of this document since the device's 2013 CE certification, reflecting a regular cadence of accumulated post-market data. The next meaningful landmark would be an independent randomised trial comparing ChondroFiller against microfracture in matched focal-defect populations at equivalent follow-up; until that exists, the cross-study reoperation figures remain an informative but imperfect benchmark.

Who is a suitable candidate and next steps

The clinical profile for ChondroFiller candidacy is fairly specific. Evidence across the CER v09 dataset covers patients with focal articular cartilage defects graded III or IV on the International Cartilage Repair Society scale — areas of full or near-full thickness loss measuring up to 3–6 cm², with structurally sound cartilage at the margins. Generalised joint wear and diffuse osteoarthritis fall outside the device's indication and outside the evidence base described in this article.

Knee defects represent the largest data pool — IKDC and MOCART data now extend to three-year follow-up in some cohorts — but published series also cover hip, ankle, shoulder, wrist, and smaller joints. The scaffold mechanism does not change between sites; what varies is the volume of outcome data available for each joint location.

Confirming candidacy requires imaging capable of characterising defect dimensions and grade. MRI identifies defect depth, surface area, and the condition of the surrounding cartilage borders that determine whether a lesion is contained and suitable. Where relevant, AI-assisted MRI review — such as the onMRI™ platform used at MSK Doctors — can add precision to that pre-treatment assessment.

At MSK Doctors, ChondroFiller is administered as an ultrasound-guided outpatient injection: no surgical admission, no general anaesthetic, no theatre waiting list. Assessment is available at clinics in Sleaford and Grantham without a GP referral; London-based patients can access the same treatment pathway through the London Cartilage Clinic.